Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
ContributorsØrnbjerg, Lykke Midtbøll; Brahe, Cecilie Heegaard; Askling, Johan; Ciurea, Adrian; Mann, Herman; Onen, Fatos; Kristianslund, Eirik Klami; Nordström, Dan; Santos, Maria Jose; Codreanu, Catalin; Gómez-Reino, Juan; Rotar, Ziga; Gudbjornsson, Bjorn; Di Giuseppe, Daniela; Nissen, Michaël; Pavelka, Karel; Birlik, Merih; Kvien, Tore; Eklund, Kari Kalervo; Barcelos, Anabela; Ionescu, Ruxandra; Sanchez-Piedra, Carlos; Tomsic, Matija; Geirsson, Árni Jón; Loft, Anne Gitte; van der Horst-Bruinsma, Irene; Jones, Gareth; Iannone, Florenzo; Hyldstrup, Lise; Krogh, Niels Steen; Hetland, Merete Lund; Østergaard, Mikkel
Published inAnnals of the Rheumatic Diseases, vol. 78, no. 11, p. 1536-1544
Publication date2019
Abstract
Keywords
- DMARDS (biologic)
- Anti-TNF
- Epidemiology
- Outcomes research
- Spondyloarthritis
Affiliation entities
Research groups
Citation (ISO format)
ØRNBJERG, Lykke Midtbøll et al. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. In: Annals of the Rheumatic Diseases, 2019, vol. 78, n° 11, p. 1536–1544. doi: 10.1136/annrheumdis-2019-215427
Main files (1)
Article (Published version)
Identifiers
- PID : unige:135501
- DOI : 10.1136/annrheumdis-2019-215427
- PMID : 31431486
Journal ISSN0003-4967
